These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 8013154

  • 1. Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer.
    Labrie F, Dupont A, Cusan L, Gomez JL, Diamond P.
    Clin Invest Med; 1993 Dec; 16(6):493-8. PubMed ID: 8013154
    [Abstract] [Full Text] [Related]

  • 2. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguère M, Borsanyi JP, Lacourciere Y, Bélanger A, Lachance R, Emond J, Monfette G.
    Prog Clin Biol Res; 1988 Dec; 260():41-62. PubMed ID: 3283766
    [Abstract] [Full Text] [Related]

  • 3. Combination therapy with flutamide and [D-Trp6, des-Gly-NH2(10)]LHRH ethylamide in stage C and D prostate cancer: today's therapy of choice--rationale and 5-year clinical experience.
    Labrie F, Dupont A, Cusan L, Bélanger A, Giguère M, Labrie C, Lacourcière Y, Monfette G, Emond J.
    Prog Clin Biol Res; 1988 Dec; 262():11-63. PubMed ID: 3287388
    [No Abstract] [Full Text] [Related]

  • 4. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer.
    Pummer K, Lehnert M, Stettner H, Hubmer G.
    Eur Urol; 1997 Dec; 32 Suppl 3():81-5. PubMed ID: 9267791
    [Abstract] [Full Text] [Related]

  • 5. Stimulation of the circulating levels of glycoprotein hormone alpha-subunit after combined administration of a luteinizing hormone-releasing hormone (LHRH) agonist and flutamide in patients with cancer of the prostate.
    St-Arnaud R, Lachance R, Dupont A, Labrie F.
    Clin Invest Med; 1986 Nov; 9(4):215-21. PubMed ID: 2433088
    [Abstract] [Full Text] [Related]

  • 6. Endocrine treatment of prostate cancer.
    Tammela T.
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [Abstract] [Full Text] [Related]

  • 7. Advantages of the combination therapy in previously untreated and treated patients with advanced prostate cancer.
    Labrie F, Dupont A, Giguere M, Borsanyi JP, Belanger A, Lacourciere Y, Emond J, Monfette G.
    J Steroid Biochem; 1986 Nov; 25(5B):877-83. PubMed ID: 3100871
    [Abstract] [Full Text] [Related]

  • 8. Endocrine effects of combined treatment with an LHRH agonist in association with flutamide in metastatic prostatic carcinoma.
    Bélanger A, Labrie F, Dupont A, Brochu M, Cusan L.
    Clin Invest Med; 1988 Oct; 11(5):321-6. PubMed ID: 2972431
    [Abstract] [Full Text] [Related]

  • 9. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer.
    Eisenberger MA, Blumenstein BA, Crawford ED, Miller G, McLeod DG, Loehrer PJ, Wilding G, Sears K, Culkin DJ, Thompson IM, Bueschen AJ, Lowe BA.
    N Engl J Med; 1998 Oct 08; 339(15):1036-42. PubMed ID: 9761805
    [Abstract] [Full Text] [Related]

  • 10. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 11. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
    Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Fazekas AT, Raynaud JP, Husson JM.
    Clin Invest Med; 1982 Jul 01; 5(4):267-75. PubMed ID: 6819101
    [Abstract] [Full Text] [Related]

  • 12. Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer.
    Pummer K.
    Semin Oncol; 1991 Oct 01; 18(5 Suppl 6):26-8. PubMed ID: 1948120
    [Abstract] [Full Text] [Related]

  • 13. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial.
    Labrie F, Dupont A, Cusan L, Gomez J, Diamond P, Koutsilieris M, Suburu R, Fradet Y, Lemay M, Têtu B.
    Clin Invest Med; 1993 Dec 01; 16(6):499-509. PubMed ID: 8013155
    [Abstract] [Full Text] [Related]

  • 14. Endocrine therapy for prostate cancer.
    Labrie F.
    Endocrinol Metab Clin North Am; 1991 Dec 01; 20(4):845-72. PubMed ID: 1778180
    [Abstract] [Full Text] [Related]

  • 15. Health-related quality of life among patients with metastatic prostate cancer.
    Albertsen PC, Aaronson NK, Muller MJ, Keller SD, Ware JE.
    Urology; 1997 Feb 01; 49(2):207-16; discussion 216-7. PubMed ID: 9037282
    [Abstract] [Full Text] [Related]

  • 16. Hormone therapy of prostatic bone metastases.
    Huben RP.
    Adv Exp Med Biol; 1992 Feb 01; 324():305-16. PubMed ID: 1492625
    [Abstract] [Full Text] [Related]

  • 17. [First line therapy in the treatment of metastatic prostate cancer].
    Sakai H, Kanetake H.
    Gan To Kagaku Ryoho; 2003 Jan 01; 30(1):43-9. PubMed ID: 12557704
    [Abstract] [Full Text] [Related]

  • 18. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in previously untreated patients with clinical stage D2 prostate cancer: today's therapy of choice.
    Labrie F, Dupont A, Cusan L, Giguere M, Bergeron N, Borsanyi JP, Lacourciere Y, Belanger A, Emond J, Monfette G.
    J Steroid Biochem; 1988 Jan 01; 30(1-6):107-17. PubMed ID: 3290578
    [Abstract] [Full Text] [Related]

  • 19. National Cancer Institute study of luteinizing hormone-releasing hormone plus flutamide versus luteinizing hormone-releasing hormone plus placebo.
    Benson RC, Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Dorr FA.
    Semin Oncol; 1991 Oct 01; 18(5 Suppl 6):9-12. PubMed ID: 1948121
    [Abstract] [Full Text] [Related]

  • 20. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F, Dupont A, Belanger A, Lefebvre FA, Raynaud JP.
    J Pharmacol; 1983 Oct 01; 14 Suppl 3():117-35. PubMed ID: 6423907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.